NIAID issues new awards to fund “pan-coronavirus” vaccines  

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants. The awards are intended to fuel vaccine research for a diverse family of coronaviruses, with a primary focus on potential pandemic-causing coronaviruses, such as SARS-CoV-2.  

“The available Covid-19 vaccines have proven to be remarkably effective at protecting against severe disease and death,” said NIAID Director Anthony Fauci. “These new awards are designed to look ahead and prepare for the next generation of coronaviruses with pandemic potential.”  

The awards are designed to fund multidisciplinary teams at each institution to conduct research focused on incorporating understanding of coronavirus virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus vaccine candidates that provide broad protective immunity to multiple coronavirus strains. Specific programmes will address coronavirus diversity and infectious potential in humans, include innovative immunogen design and vaccine platforms, and approaches to elicit potent and durable pan-coronavirus immunity, and evaluate vaccine candidates in preclinical models. The awardees are expected to be flexible in the response to emerging knowledge about SARS-CoV-2 immune responses and infection and factor in new information as vaccines candidates are developed. Additional awards are expected to be issued under the NOSI in 2022 to support pan-coronavirus vaccine research at more institutions.  

The new awards build on the $1.2 billion investment NIAID has made in coronavirus vaccine research since the Covid-19 pandemic began, including multiple projects in pan-coronavirus vaccine research in the NIAID intramural and extramural programmes. 

The following awards have been issued:  

University of Wisconsin, Madison    

Project Title: PanCorVac (Center for Pan-Coronavirus Vaccine Development)  

Brigham and Women’s Hospital, Boston  

Project Title: Discovering Durable Pan-Coronavirus Immunity  

Duke University, Durham, North Carolina  

Project Title: Design and Development of a Pan-Betacoronavirus Vaccine  

Image credit: Giorgio Trovato

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free